skip to Global Navigation Bar skip to main content

homeHome > About Us > Press Release > News


News Content
Daewoong Pharmaceutical’s botulinum toxin becomes the first Korea-made Botulinum Toxin to obtain US FDA approval
Date 2019-02-02 Hit 2820
News List
Prev Daewoong’s Hyangnam Plant acquires International Standard ISO 45001 (Safety & Health Management Systems)
Next Daewoong Pharmaceutical leads innovation of local business by focusing on technology transfer with Trapaco, the largest pharmaceuticals company in Vietnam.